Atika Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Atika Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,500	Closed	-$8.94M	–	107
2024 Q3	$8.94M	Sell	8,500 -1,000	-11%	-$1.11M	0.92%	40
2024 Q2	$9.98M	Buy	9,500 +700	+8%	+$679K	0.98%	32
2024 Q1	$8.47M	Buy	+8,800	New	+$8.37M	0.83%	46
2023 Q2	–	Sell	-9,690	Closed	-$7.96M	–	100
2023 Q1	$7.96M	Buy	+9,690	New	+$7.31M	1.18%	30
2020 Q4	–	Sell	-14,200	Closed	-$7.95M	–	137
2020 Q3	$7.95M	Buy	14,200 +1,700	+14%	+$1.03M	0.65%	51
2020 Q2	$7.8M	Buy	12,500 +9,453	+310%	+$5.37M	1.01%	38
2020 Q1	$1.49M	Buy	+3,047	New	+$1.26M	0.29%	75
2017 Q3	–	Sell	-9,500	Closed	-$4.67M	–	89
2017 Q2	$4.67M	Buy	9,500 +2,500	+36%	+$1.09M	1.63%	16
2017 Q1	$2.71M	Buy	+7,000	New	+$2.59M	1.33%	37

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atika Capital Management's REGN Position: Q4 2024 in Review

Atika Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 8,500 shares — an estimated $8.94M sold.

Atika Capital Management first reported a position in REGN in Q1 2017 and held it in 9 quarters. The position peaked at $9.98M in Q2 2024. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Atika Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Atika Capital Management sold 8,500 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $8.94M.
Atika Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 9 quarters.
Atika Capital Management's Regeneron Pharmaceuticals position peaked at $9.98M in Q2 2024.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Atika Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.